Targeting a specific immune pathway to improve transplant outcomes
The impact of targeting CD40-CD154 pathway in nonhuman primate vascularized composite allograft model
This study is looking at a new way to help patients with severe tissue damage who need complex transplants by using a special treatment to improve the chances that their new tissue will be accepted by their body and last longer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11129160 on NIH RePORTER |
What this research studies
This research investigates how targeting the CD40-CD154 pathway can enhance the success of vascular composite allotransplantation (VCA), a procedure for patients with severe tissue damage. The study uses a nonhuman primate model to explore the effectiveness of a specific antibody in promoting long-term graft survival and reducing rejection rates. By focusing on the immune response involved in transplant rejection, the research aims to develop better immunosuppressive strategies tailored for VCA patients. This approach could lead to improved outcomes for individuals receiving complex tissue transplants.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals requiring vascular composite allotransplantation due to severe tissue damage or deformities.
Not a fit: Patients who are not candidates for vascular composite allotransplantation or those with conditions unrelated to tissue grafting may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients undergoing complex tissue transplants, resulting in better graft survival and fewer complications.
How similar studies have performed: Previous research has shown promising results in targeting the CD40-CD154 pathway for improving transplant outcomes, indicating potential for success in this approach.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Kwun, Jean — Duke University
- Study coordinator: Kwun, Jean
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.